Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Yin, Hao ^a,b   Park, Soo Young ^a   Wang, Xiao Jun ^a,c   Misawa, Ryosuke ^a,d   Grossman, Eric J ^a,e   Tao, Jing ^a,f   Zhong, Rong ^a   Witkowski, Piotr ^a   Bell, Graeme I ^a   Chong, Anita S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF MIAMI   (United States)

^e NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^f First People s Hospital of Yunnan Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAPAMYCIN; STREPTOZOCIN; TACROLIMUS; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; IMMUNOSUPPRESSIVE AGENT; INS1 PROTEIN, MOUSE; INSULIN; LUCIFERASE; PIPERIDINE DERIVATIVE; URACIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CELL FUNCTION; CELL ISOLATION; CELL LOSS; CELL REGENERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INSULIN RELEASE; LIPID METABOLISM; LOADING DRUG DOSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROMOTER REGION; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; CHEMICALLY INDUCED; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LUMINESCENCE; METABOLISM; REGENERATION; REPORTER GENE; TRANSPLANTATION;

MUS; MUS MUSCULUS;

ANIMALS; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; GENES, REPORTER; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN-SECRETING CELLS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; PIPERIDINES; PROMOTER REGIONS, GENETIC; REGENERATION; SIROLIMUS; STREPTOZOCIN; TACROLIMUS; THIAZOLIDINEDIONES; URACIL;

EID: 84878777152     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065777     Document Type: Article

References (68)

1. Weir GC, Bonner-Weir S, (2004) Beta-cell precursors-a work in progress. Nat Biotechnol 22: 1095-1096.
2. Dor Y, Brown J, Martinez OI, Melton DA, (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429: 41-46.
3. Finegood DT, Scaglia L, Bonner-Weir S, (1995) Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 44: 249-256.
4. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, et al. (1998) Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47: 358-364.
5. Montanya E, Nacher V, Biarnes M, Soler J, (2000) Linear correlation between beta-cell mass and body weight throughout the lifespan in Lewis rats: role of beta-cell hyperplasia and hypertrophy. Diabetes 49: 1341-1346.
6. Grossman EJ, Lee DD, Tao J, Wilson RA, Park SY, et al. (2010) Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PLoS One 5: e8749.
7. Lee HC, Bonner-Weir S, Weir GC, Leahy JL, (1989) Compensatory adaption to partial pancreatectomy in the rat. Endocrinology 124: 1571-1575.
8. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T, (2008) Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 29: 334-350.
9. Sorenson RL, Brelje TC, (1997) Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res 29: 301-307.
10. Kushner JA, Ciemerych MA, Sicinska E, Wartschow LM, Teta M, et al. (2005) Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol 25: 3752-3762.
11. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, et al. (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391: 900-904.
12. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC, (2005) Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48: 2221-2228.
13. Zhao YF, Feng DD, Chen C, (2006) Contribution of adipocyte-derived factors to beta-cell dysfunction in diabetes. Int J Biochem Cell Biol 38: 804-819.
14. Karges B, Durinovic-Bello I, Heinze E, Boehm BO, Debatin KM, et al. (2004) Complete long-term recovery of beta-cell function in autoimmune type 1 diabetes after insulin treatment. Diabetes Care 27: 1207-1208.
15. Rankin MM, Kushner JA, (2009) Adaptive beta-cell proliferation is severely restricted with advanced age. Diabetes 58: 1365-1372.
16. Tschen SI, Dhawan S, Gurlo T, Bhushan A, (2009) Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes 58: 1312-1320.
17. Yin D, Tao J, Lee DD, Shen J, Hara M, et al. (2006) Recovery of islet beta-cell function in streptozotocin- induced diabetic mice: an indirect role for the spleen. Diabetes 55: 3256-3263.
18. Kodama S, Kuhtreiber W, Fujimura S, Dale EA, Faustman DL, (2003) Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302: 1223-1227.
19. Chong AS, Shen J, Tao J, Yin D, Kuznetsov A, et al. (2006) Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 311: 1774-1775.
20. Nishio J, Gaglia JL, Turvey SE, Campbell C, Benoist C, et al. (2006) Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 311: 1775-1778.
21. Suri A, Calderon B, Esparza TJ, Frederick K, Bittner P, et al. (2006) Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science 311: 1778-1780.
22. Kushner JA, Weir GC, Bonner-Weir S, (2010) Ductal origin hypothesis of pancreatic regeneration under attack. Cell Metab 11: 2-3.
23. Li WC, Rukstalis JM, Nishimura W, Tchipashvili V, Habener JF, et al. (2010) Activation of pancreatic-duct-derived progenitor cells during pancreas regeneration in adult rats. J Cell Sci 123: 2792-2802.
24. Park SY, Bell GI, (2009) Noninvasive monitoring of changes in pancreatic beta-cell mass by bioluminescent imaging in MIP-luc transgenic mice. Horm Metab Res 41: 1-4.
25. Park SY, Wang X, Chen Z, Powers AC, Magnuson MA, et al. (2005) Optical imaging of pancreatic beta cells in living mice expressing a mouse insulin I promoter-firefly luciferase transgene. Genesis 43: 80-86.
26. Virostko J, Chen Z, Fowler M, Poffenberger G, Powers AC, et al. (2004) Factors influencing quantification of in vivo bioluminescence imaging: application to assessment of pancreatic islet transplants. Mol Imaging 3: 333-342.
27. Virostko J, Radhika A, Poffenberger G, Chen Z, Brissova M, et al. (2010) Bioluminescence imaging in mouse models quantifies beta cell mass in the pancreas and after islet transplantation. Mol Imaging Biol 12: 42-53.
28. Smith SJ, Zhang H, Clermont AO, Powers AC, Kaufman DB, et al. (2006) In vivo monitoring of pancreatic beta-cells in a transgenic mouse model. Mol Imaging 5: 65-75.
29. Chen X, Zhang X, Larson C, Xia G, Kaufman DB, (2008) Prolonging islet allograft survival using in vivo bioluminescence imaging to guide timing of antilymphocyte serum treatment of rejection. Transplantation 85: 1246-1252.
30. Fowler M, Virostko J, Chen Z, Poffenberger G, Radhika A, et al. (2005) Assessment of pancreatic islet mass after islet transplantation using in vivo bioluminescence imaging. Transplantation 79: 768-776.
31. Yin D, Ding JW, Shen J, Ma L, Hara M, et al. (2006) Liver ischemia contributes to early islet failure following intraportal transplantation: benefits of liver ischemic-preconditioning. Am J Transplant 6: 60-68.
32. Wu T, Levay-Young B, Heuss N, Sozen H, Kirchhof N, et al. (2002) Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy. Transplantation 74: 22-27.
33. Bertera S, Crawford ML, Alexander AM, Papworth GD, Watkins SC, et al. (2003) Gene transfer of manganese superoxide dismutase extends islet graft function in a mouse model of autoimmune diabetes. Diabetes 52: 387-393.
34. Pileggi A, Molano RD, Berney T, Cattan P, Vizzardelli C, et al. (2001) Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes 50: 1983-1991.
35. Mooradian AD, Chehade J, Thurman JE, (2002) The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treat Endocrinol 1: 13-20.
36. Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K, (2005) Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab 288: E510-518.
37. Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, et al. (2004) Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes 53: 2844-2854.
38. Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, et al. (2004) Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. Metabolism 53: 488-494.
39. Diani AR, Sawada G, Wyse B, Murray FT, Khan M, (2004) Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 286: E116-122.
40. Takamura T, Ando H, Nagai Y, Yamashita H, Nohara E, et al. (1999) Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res Clin Pract 44: 107-114.
41. Anjaneyulu M, Ramarao P, (2003) Protective effect of pioglitazone against multiple low-dose streptozotocin-induced diabetes in rats. Methods Find Exp Clin Pharmacol 25: 205-208.
42. Baetta R, Corsini A, (2011) Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 71: 1441-1467.
43. Barnett A, (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60: 1454-1470.
44. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, et al. (2003) Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52: 741-750.
45. Molano RD, Pileggi A, Berney T, Poggioli R, Zahr E, et al. (2003) Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. Transplantation 75: 1812-1819.
46. Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y, (2011) Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab 13: 1028-1035.
47. Rieck S, White P, Schug J, Fox AJ, Smirnova O, et al. (2009) The transcriptional response of the islet to pregnancy in mice. Mol Endocrinol 23: 1702-1712.
48. Group C (2009) 2007 update on allogeneic islet transplantation from the Collaborative Islet Transplant Registry (CITR). Cell Transplant 18: 753-767.
49. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, et al. (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54: 2060-2069.
50. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, et al. (2012) Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 35: 1436-1445.
51. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230-238.
52. Faradji RN, Froud T, Messinger S, Monroy K, Pileggi A, et al. (2009) Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction. Cell Transplant 18: 1247-1259.
53. Ryu S, Kodama S, Ryu K, Schoenfeld DA, Faustman DL, (2001) Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. J Clin Invest 108: 63-72.
54. Guz Y, Nasir I, Teitelman G, (2001) Regeneration of pancreatic beta cells from intra-islet precursor cells in an experimental model of diabetes. Endocrinology 142: 4956-4968.
55. Lohr M, Kloppel G, (1987) Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 30: 757-762.
56. Nakanishi K, Kobayashi T, Miyashita H, Okubo M, Sugimoto T, et al. (1993) Relationships among residual beta cells, exocrine pancreas, and islet cell antibodies in insulin-dependent diabetes mellitus. Metabolism 42: 196-203.
57. Rother KI, Harlan DM, (2004) Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest 114: 877-883.
58. Suarez-Pinzon WL, Yan Y, Power R, Brand SJ, Rabinovitch A, (2005) Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 54: 2596-2601.
59. Ogawa N, List JF, Habener JF, Maki T, (2004) Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53: 1700-1705.
60. Yang Z, Chen M, Carter JD, Nunemaker CS, Garmey JC, et al. (2006) Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem Biophys Res Commun 344: 1017-1022.
61. Wang M, Racine JJ, Song X, Li X, Nair I, et al. (2012) Mixed chimerism and growth factors augment beta cell regeneration and reverse late-stage type 1 diabetes. Sci Transl Med 4: 133ra159.
62. Fosgerau K, Jessen L, Lind Tolborg J, Osterlund T, Schaeffer Larsen K, et al. (2012) The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db/db mice. Diabetes Obes Metab.
63. Xu G, Stoffers DA, Habener JF, Bonner-Weir S, (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276.
64. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, et al. (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635.
65. Baggio LL, Drucker DJ, (2006) Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 57: 265-281.
66. Chia CW, Egan JM, (2008) Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 93: 3703-3716.
67. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H, (2009) Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 157: 415-426.
68. Kawashima S, Matsuoka TA, Kaneto H, Tochino Y, Kato K, et al. (2011) Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice. Biochem Biophys Res Commun 404: 534-540.